Description
A sulfonamide antibiotic and nonpeptide ET receptor antagonist (IC50s = 0.6 and 22 μM for the ETA and ETB receptors, respectively); inhibits the growth of Gram-positive and Gram-negative bacteria in vitro, including S. pneumoniae, B. subtilis, S. epidermidis, E. coli, and K. pneumoniae (MICs = 1.95, 0.98, 7.81, 62.5, and 7.81 μg/mL, respectively); inhibits phosphoinositide turnover stimulated by ET-1 in TE671 cells; inhibits ET-induced contraction of rat pulmonary artery rings ex vivo at 0.1 and 1 mM; reduces atrial natriuretic peptide levels in myocytes and plasma and increases survival in a rat model of pulmonary hypertension induced by MCT at 1,000 mg/kg per day; blocks MCT-induced increases in pulmonary artery blood pressure at 300 and 1,000 mg/kg
Formal name: 4-amino-N-(3,4-dimethyl-5-isoxazolyl)-benzenesulfonamide
Synonyms: NSC 13120|NSC 33807|NSC 38588|NSC 683536|Sulfafurazole
Molecular weight: 267.3
CAS: 127-69-5
Purity: ≥98%
Formulation: A solid
Product Type|Biochemicals|Antibiotics|Sulfonamides||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases|Pneumonia